Firalis Molecular Precision provides to its customers a broad range of omics technologies to help them scale by increasing their analytical capacities in the most flexible and customizable way.
We are a certified service provider for Olink Explore HT, Target 96/48 and Flex running the Target 48 and Flex in GCLP mode.

Firalis Molecular Precision is the preferred partner for patient’s sample management thanks to a strong expertise in protocol design, biobanking, and multidimensional samples analysis. Whether it is in the patient’s perspective for diagnostic, prognostic, prediction and monitoring of the disease progression; or from the drug’s perspective to evaluate toxicity and efficiency.

Beyond its multi-omic approach, analytical capacities and scientific expertise, Firalis group is an end-to-end partner which offers clinical qualification, biobanking infrastructure, assay development, bioanalytical testing, data analysis and production facilities to empower your team and fasten your projects.

Genomics:
Firalis Molecular Precision is a French high throughput sequencing center equipped with the latest Illumina X Plus platform, NextSeq 2000 and NovaSeq 6000Dx. We provide all the platforms and experts required to perform genomic and transcriptomic analysis from DNA/RNA extraction to qPCR or DNA/RNA sequencing according to your requirements in terms of price, sensibility, analytes and acquisition time.
In addition, the cutting-edge single cell analysis system brings powerful oncological section analysis, allowing study and characterization of the Tumor Microenvironment on a cell-by-cell basis.
Our company offers a complete range of genomic analysis including detection of SNPs, CNVs, variants, ctDNA, gene identification, species identification, and genome structural organization. About transcriptomic, we provide whole transcriptomes to targeted sequencing analysis, allowing identification of novel transcripts, alternative splicing and differential gene transcription quantification. The characterization of rare cell types and biomarkers is also assessed on a cell-by-cell basis.

Proteomics:
When it comes to proteomic, our scientific team offers a large panel of services, ranging from large screening and new drug target discovery (Olink Explore HT, Explore 3072 and Explore 384) to target validation and monitoring with Olink Target 48/Flex; Luminex, MSD or ELLA to the extremely sensitive technologies such as the Quanterix SR-X and SP-X. More than a hundred of analytes are already validated on our platforms.

Firalis group is certified ISO 13485 (GMP compliant) and ISO 9001 for the development and production of CE-marked assays, certified ISO20287 for its biobank and accredited CAP for testing laboratory, including NGS and genotyping. Lab staff is trained GCLP and we are ISO14001 for environmental management.